Everest Medicines Announces Publication of Etrasimod's Asian Multicenter Phase III ENLIGHT UC study (ES101002) Results in The Lancet Gastroenterology & Hepatology
Oct 09, 2025 18:24 HKT |  |
|
Hua Medicine Announces the Pharmaceutical Service of Hong Kong Department of Health of China has Officially Accepted the Application for Marketing Authorization of the New Drug Dorzagliatin
Sep 29, 2025 11:22 HKT |  |
|
China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication
Sep 28, 2025 15:00 HKT |  |
|
China Medical System (867.HK; 8A8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies
Sep 23, 2025 12:15 HKT | |
|
HKTDC releases research report on biomedicine, Industry development drives GBA global tech leadership
Sep 15, 2025 15:19 HKT |  |
|
AGFA HealthCare Strengthens Market Position in KLAS Enterprise Imaging Report 2025
Sep 11, 2025 04:00 HKT |  |
|
Elevating Imaging, Empowering Flow - AGFA HealthCare at RSNA 2025
Sep 09, 2025 16:00 HKT | |
|
Everest Medicines Announces 2025 Interim Results: 'Dual-Engine' Strategy Driving Strong Synergies Between Commercialization and R&D
Sep 01, 2025 20:55 HKT | |
|
Hua Medicine Announces 2025 Interim Results
Aug 28, 2025 17:07 HKT | |
|
Resilient Interim Results, Essex Bio-Technology Drives Growth and Innovation
Aug 26, 2025 20:00 HKT |  |
|
Lepu Biopharma (2157.HK) announces 2025 interim results
Aug 21, 2025 14:38 HKT |  |
|
Innovative Vaccine Engine Continues to Drive Growth: CanSinoBIO Enters a New Growth Cycle
Aug 20, 2025 20:30 HKT |  |
|
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers
Aug 19, 2025 15:00 HKT | |
|
Sino Biopharm (1177.HK) Announces 2025 Interim Results
Aug 18, 2025 19:11 HKT |  |
|
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC
Aug 15, 2025 20:15 HKT | |
|
Everest Medicines' New Drug Application for Etrasimod Accepted in Taiwan, Marking Another Milestone in Asia Market Access
Aug 14, 2025 18:00 HKT | |
|
NMPA Accepted Essex's Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration
Aug 13, 2025 20:24 HKT | |
|
Kangji Medical Receives Privatisation Proposal from a Consortium Led by Kangji Medical's Chairman, Zhong Ming, TPG and QIA to Advance Long-Term Strategic Vision
Aug 13, 2025 11:27 HKT |  |
|
Everest Medicines Announces Full Approval of NEFECON(R) in Taiwan
Aug 08, 2025 18:09 HKT | |
|
NEFECON(R) Receives NMPA Approval for Production Expansion in China, as Everest Medicines Accelerates Accessibility and Capacity Efforts
Aug 05, 2025 10:21 HKT | |
|